Session 3 – Accelerating Biomedical Innovations
Date: 22 July (Wednesday) 12:20 – 13:50 (GMT+8)
Venue: 701EF, 7F, TaiNEX2 / Online event platform
Stephen is Director of New Ventures at Johnson & Johnson Innovation, Asia Pacific. In this role, he is responsible for the deployment of the APIC strategy in North Asia by identifying opportunities (in Pharmaceuticals, Consumer Healthcare and Medical Device) and building networks within the innovation ecosystem.
Stephen has over 20 years of experience in the life science sector. Prior to joining Johnson & Johnson, Stephen was the Managing Director of Kybora EM (formerly Torreya EM) where he was responsible for Asia Pacific business development focusing on licensing and M&A advisory services. Stephen is experienced in bringing together investment opportunities and funding. He has been the founder and CEO of CASiGEN Pharma (a Ventac portfolio company) and BioMatrix Dx. He also served as a partner at Ventac Partners where he played a key role in portfolio company building, strategy, marketing, product analysis and IP development. He has also worked as a consultant for 3V SourceOne Capital, Applied Strategies Consulting, First State Investments, and as a patent examiner for the USPTO.
Stephen received his D.Phil. in Biochemistry from the University of Oxford, Merton College. He holds an MBA from the University of Chicago Booth School of Business.
Speech title & Synopsis
Leading a panel of VCs, Biotech executives, J&J business leaders and head of research institutes to get insight on partnering with big pharma and accessing the global market.